Spondylo-megaepiphyseal-metaphyseal dysplasia

Spondylo-megaepiphyseal-metaphyseal dysplasia (SMMD) is an extremely rare inherited skeletal disorder characterized by abnormalities of the spine (spondylo-), abnormally large epiphyses (megaepiphyseal), and metaphyseal irregularities of the long bones. This condition primarily affects the skeletal system, leading to disproportionate short stature that typically becomes apparent in early childhood. Key clinical features include short-limbed dwarfism, platyspondyly (flattened vertebral bodies), enlarged and dysplastic epiphyses particularly at the knees and hips, widened and irregular metaphyses, and progressive joint stiffness. Patients may also develop waddling gait, genu valgum (knock knees), and upper limb involvement with limited range of motion at the elbows and wrists. Radiographic findings are distinctive and include large, fragmented-appearing epiphyses with irregular ossification and metaphyseal flaring and irregularity. The condition was first described in a small number of families, and the molecular basis has been linked to mutations in the NKX3-2 gene (also known as BAPX1), which encodes a transcription factor important in skeletal development, particularly in chondrocyte differentiation and joint formation. The disorder follows an autosomal recessive inheritance pattern. There is currently no specific cure or disease-modifying treatment for SMMD. Management is supportive and symptomatic, focusing on orthopedic surveillance, physical therapy to maintain joint mobility, pain management, and surgical intervention when necessary for significant skeletal deformities. Regular monitoring by a multidisciplinary team including clinical geneticists, orthopedic surgeons, and rehabilitation specialists is recommended.

Common questions about Spondylo-megaepiphyseal-metaphyseal dysplasia